📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. (2022)

First Author: Wilke AC

Attributed to: Joint Wellcome and MRC Centre, ‘Wellcome Trust – Medical Research Council Cambridge Stem Cell Institute’ funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1182/blood.2021012081

PubMed Identifier: 34624079

Publication URI: http://europepmc.org/abstract/MED/34624079

Type: Journal Article/Review

Volume: 139

Parent Publication: Blood

Issue: 4

ISSN: 0006-4971